[go: up one dir, main page]

MX2010005690A - Variantes de proteasa para uso farmaceutico. - Google Patents

Variantes de proteasa para uso farmaceutico.

Info

Publication number
MX2010005690A
MX2010005690A MX2010005690A MX2010005690A MX2010005690A MX 2010005690 A MX2010005690 A MX 2010005690A MX 2010005690 A MX2010005690 A MX 2010005690A MX 2010005690 A MX2010005690 A MX 2010005690A MX 2010005690 A MX2010005690 A MX 2010005690A
Authority
MX
Mexico
Prior art keywords
variants
pharmaceutical use
treatment
protease variants
diabetes type
Prior art date
Application number
MX2010005690A
Other languages
English (en)
Inventor
Allan Svendsen
Peter Colin Gregory
Signe Eskildsen Larsen
Lars Beier
Thomas Lenhard
Tanja Maria Rosenkilde Kjaer
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of MX2010005690A publication Critical patent/MX2010005690A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención se relaciona con variantes nuevas de una proteasa derivada del Nocardiopsis sp. (SEQ ID NO:1) y proteasas relacionadas de cerca, así como su uso farmacéutico. Las variantes muestran funcionamiento mejorado en el tratamiento de insuficiencia exocrina pancreática (PEI). Las variantes pueden ser combinadas con una lipasa y/o una amilasa. Otros ejemplos de indicaciones médicas son: tratamiento de trastornos digestivos, pancreatitis, fibrosis quística, diabetes tipo I, y/o diabetes tipo II.
MX2010005690A 2007-12-04 2008-12-02 Variantes de proteasa para uso farmaceutico. MX2010005690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07122243 2007-12-04
PCT/EP2008/066646 WO2009071550A1 (en) 2007-12-04 2008-12-02 Protease variants for pharmaceutical use

Publications (1)

Publication Number Publication Date
MX2010005690A true MX2010005690A (es) 2010-06-08

Family

ID=40310217

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005690A MX2010005690A (es) 2007-12-04 2008-12-02 Variantes de proteasa para uso farmaceutico.

Country Status (15)

Country Link
US (1) US8455235B2 (es)
EP (1) EP2220220A1 (es)
JP (1) JP2011505160A (es)
KR (1) KR20100092450A (es)
CN (1) CN101889084A (es)
AR (1) AR071261A1 (es)
AU (1) AU2008333313A1 (es)
BR (1) BRPI0819662A2 (es)
CA (1) CA2707658A1 (es)
IL (1) IL205952A0 (es)
MX (1) MX2010005690A (es)
RU (1) RU2010127329A (es)
TW (1) TW200936158A (es)
WO (1) WO2009071550A1 (es)
ZA (1) ZA201003576B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509603A (ja) * 2003-10-10 2007-04-19 ノボザイムス アクティーゼルスカブ プロテアーゼ変異型
EP2258839B1 (en) 2004-06-21 2015-06-03 Novozymes A/S Proteases
JP5421117B2 (ja) * 2006-12-22 2014-02-19 ノボザイムス アクティーゼルスカブ イースト抽出物を製造する方法
FR2972639B1 (fr) * 2011-03-18 2013-11-08 Top Pharm Lab Composition pharmaceutique anti-inflammatoire
BR112013032861A2 (pt) 2011-07-22 2017-01-24 Novozymes North America Inc métodos para aumentar a atividade da enzima celulolítica durante a hidrólise do material celulósico, para hidrolisar um material celulósico pré-tratado, para a produção de um produto da fermentação, e para a fermentação de um material celulósico pré-tratado
US20130273026A1 (en) * 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
EP4525615A2 (en) 2022-05-14 2025-03-26 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK564086A (da) 1986-11-25 1988-06-17 Novo Industri As Enzymatisk detergent-additiv
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
DE69634248T2 (de) * 1995-05-31 2006-01-12 Medzyme N.V. Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen
NL1001620C2 (en) 1995-06-22 1996-12-24 Instituut Voor Agrobiologisch Improvement in activity of plant growth regulators
FR2747045B1 (fr) 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
DE50002450D1 (de) * 1999-03-17 2003-07-10 Solvay Pharm Gmbh Enzyme zur behandlung von diabetes mellitus typ i
WO2001058276A2 (en) 2000-02-08 2001-08-16 F Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
JP4137526B2 (ja) 2002-01-23 2008-08-20 Toto株式会社 ケラチナーゼおよびその製造法
AU2003250830A1 (en) 2002-06-12 2003-12-31 Bayer Healthcare Ag Regulation of human subtilase-like serine protease
WO2004111222A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Proteases
DK1639105T4 (da) 2003-06-19 2012-12-10 Novozymes As Proteases
WO2004111219A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Improved proteases and methods for producing them
JP4880453B2 (ja) 2003-06-19 2012-02-22 ノボザイムス アクティーゼルスカブ プロテアーゼ
WO2004111223A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Proteases
JP2007509603A (ja) 2003-10-10 2007-04-19 ノボザイムス アクティーゼルスカブ プロテアーゼ変異型
US7985569B2 (en) * 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
WO2005115445A1 (en) * 2004-05-24 2005-12-08 Novozymes A/S Enzymes for pharmaceutical use
EP2258839B1 (en) 2004-06-21 2015-06-03 Novozymes A/S Proteases
BRPI0611932A2 (pt) 2005-06-24 2011-01-04 Novozymes As amilase, uso da mesma, composição farmacêutica, e, método para o tratamento de uma doença
KR20080017025A (ko) 2005-06-24 2008-02-25 노보자임스 에이/에스 약학적 용도의 리파제

Also Published As

Publication number Publication date
BRPI0819662A2 (pt) 2015-06-16
RU2010127329A (ru) 2012-01-10
WO2009071550A1 (en) 2009-06-11
ZA201003576B (en) 2011-02-23
KR20100092450A (ko) 2010-08-20
IL205952A0 (en) 2010-11-30
TW200936158A (en) 2009-09-01
US20100322915A1 (en) 2010-12-23
US8455235B2 (en) 2013-06-04
AU2008333313A1 (en) 2009-06-11
AR071261A1 (es) 2010-06-09
CA2707658A1 (en) 2009-06-11
EP2220220A1 (en) 2010-08-25
JP2011505160A (ja) 2011-02-24
CN101889084A (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
DK1755656T3 (da) Enzymer til farmaceutisk anvendelse
MX2007015471A (es) Amilasas para uso farmaceutico.
TW200738256A (en) Lipases for pharmaceutical use
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
NO20080438L (no) Proteaser til farmasoytisk anvendelse
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
JP2010512795A5 (es)
MX2007005166A (es) Plantas de algodon tolerantes a la agresion.
EP4413994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
MX2009005655A (es) Composiciones y usos de un polipeptido alfa-amilasa del bacilo de la especie 195.
WO2011163648A8 (en) Cns delivery of therapeutic agents
MX354776B (es) Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
MY165889A (en) Compositions and methods of using proislet peptides and analogs thereof
MY183252A (en) Kallirein 7 modulators
WO2008112459A3 (en) Alkaliphilic bacillus species a-amylase variants, compositions comprising a-amylase variants, and methods of use
MX339810B (es) Productos de consumo con variantes de la proteasa.
GB201117669D0 (en) Enzyme delivery systems and methods of preparations and use
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721A (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม

Legal Events

Date Code Title Description
FA Abandonment or withdrawal